Introduction: Hypoglycemia fear seems to be the strongest barrier to physical activity for individuals with type 1 diabetes mellitus (T1DM). The aim of the study was to describe clinical characteristics of participants with T1DM in the intensive sporting event of runs and bike rides, and investigate factors associated with reported hypoglycemia events during the competition, in particular the use of continuous and flash glucose monitoring systems (CGM/FGM).

Methods: The sporting event took place in Spoleto, Italy from 30 August to 2 September 2018. An online survey was distributed among 150 participants with diabetes. Only T1DM patients were invited to complete the survey that included questions on baseline clinical characteristics as well as glucose control and meal related issues during the competition. Logistic regressions were used to determine factors associated with reported hypoglycemia.

Results: There were 35 T1DM individuals who completed the questionnaire; 18 subjects were CGM/FGM users, while the others performed self-measured blood glucose measurements (SMBG) on glucose meters. Mild hypoglycemia episode during the competition was reported by 4 CGM/FGM users and 6 non-users (OR:0.73, CI:0.34-1.53). No severe hypoglycemic episode was reported. BMI≥25 kg/m2 (OR:2.56, CI:1.10-5.98) and subjectively very hard or maximal intensity of the competition (OR:4.09, CI:1.51-15.89) was associated with higher risk of hypoglycemia.

Conclusions: Selected patients with T1DM can participate in intensive sport competitions with relatively low risk of hypoglycemia regardless of either CGM/FGM or SMBG use.


J. Hohendorff: Other Relationship; Self; Abbott, Ascensia Diabetes Care, Novo Nordisk A/S, Sanofi-Aventis. D. Ucieklak: None. J. Skupien: None. B. Matejko: Research Support; Self; Roche Diabetes Care. Other Relationship; Self; Ascensia Diabetes Care. A. Di Giacomo: None. M. Malecki: Advisory Panel; Self; Abbott Laboratories, AstraZeneca, Bioton, Boehringer Ingelheim Pharmaceuticals, Inc., Lilly Diabetes, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Novo Nordisk Inc., Sanofi-Aventis. Speaker’s Bureau; Self; Merck & Co., Inc. T. Klupa: Advisory Panel; Self; Abbott, AstraZeneca, Bioton, Lilly Diabetes, Novo Nordisk A/S. Employee; Spouse/Partner; Ascensia Diabetes Care. Other Relationship; Self; Ascensia Diabetes Care, Boehringer Ingelheim Pharmaceuticals, Inc., Medtronic MiniMed, Inc.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at